BICYCLE THERAPEUTICS PLC Cash Flow Statement
BCYC|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$250M
FY2025
Free Cash Flow
-$252M
FY2025
Capital Expenditures
$2M
Cash used for long-term assets
Dividends Paid
N/A
FY2025
BICYCLE THERAPEUTICS PLC used $250M in operating cash flow and negative free cash flow of $252M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.98 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
- Negative return on equity: -35.9% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$219.0M | -$169.0M | -$180.7M | -$112.7M | -$66.8M | -$51.0M | -$30.6M |
| Depreciation & Amortization | $6.4M | $7.2M | $6.5M | $3.7M | $1.4M | $1.3M | $960.0K |
| Operating Cash Flow | -$249.7M | -$164.7M | -$60.6M | -$86.1M | -$14.8M | -$17.8M | -$28.6M |
| Capital Expenditures | $2.4M | $1.2M | $2.9M | $19.0M | $2.0M | $1.2M | $1.6M |
| Free Cash Flow | -$252.0M | -$166.0M | -$63.6M | -$105.1M | -$16.8M | -$19.0M | -$30.2M |
| FCF Margin | -347.2% | -470.5% | -235.6% | -726.7% | -143.8% | -182.8% | -218.6% |